Announced Tue, 7 Jul · 15:28 IST
Routine demat confirmation certificate for Q1 FY27 filed
Compliance View source PDF
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.7%1-day move
₹703.00
prior close
₹699.20
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-2.7+0.1+0.9+2.0+0.8+1.4————
Up moveDown movePending
AI summary
Aarti Pharmalabs submitted a SEBI Regulation 74(5) certificate from its registrar MUFG Intime India for the quarter ended 30 June 2026. It confirms that share certificates received for dematerialisation were processed, listed on stock exchanges, and the depository names were updated in the register of members within prescribed timelines. This is a routine quarterly compliance filing with no business or financial impact.
Likely market impact
No material impact on shareholders; this is a standard procedural filing confirming proper handling of demat requests.